Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Soft Wearables Segment Pressures Ambarella (AMBA) Results; China IP Remains on Watch - Chardan Capital
-
Implant Sciences to Explore Strategic Options as Growing Security Needs for Soft Targets Drives Spending on Security Technologies
-
Unusual 11 Mid-Day Movers 12/2: (ONDK) (MTSN) (ADMP) Higher; (ZFGN) (OGXI) (ATV) Lower
-
Chardan Capital Markets Starts Ritter Pharmaceuticals (RTTR) at Buy
-
Giggles N’ Hugs Signs Agreement with New York-Based Chardan Capital Markets
-
Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial
-
MTBC Announces Closing of $5.8 Million Series A Cumulative Redeemable Perpetual Preferred Stock Offering and Exercise of Over-Allotment Option by Underwriters
-
MTBC Announces Closing of $5.8 Million Series A Cumulative Redeemable Perpetual Preferred Stock Offering and Exercise of Over-Allotment Option by Underwriters
-
Chardan Capital Remains Buyers of Energous (WATT) Amid Equity Raise
-
Unique Fabricating, Inc. Reports Third Quarter Revenues of $39.6 Million; Adjusted Diluted Earnings per Share of $0.18
-
Chardan Capital Positive on YOU On Demand (YOD) Deal with Ai Shang Media; Affirms at 'Buy'
-
MTBC Reports Third Quarter 2015 Results
-
MTBC Reports Third Quarter 2015 Results
-
Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital
-
Live Ventures (LIVE) Terminates ATM Engagement Agreement
-
Vascular Biogenics Ltd. Announces Closing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Unusual 11 Mid-Day Movers 11/4: (EFOI) (MXL) (GHDX) Higher; (ENPH) (FARO) (GRPN) Lower
-
Chardan Capital Markets Starts Opexa Therapeutics (OPXA) at Buy
-
Chardan Capital Markets Starts The Medicines Company (MDCO) at Buy
-
Chardan Capital Markets Upgrades Perion Network Ltd. (PERI) to Buy
-
MTBC Announces Pricing of Series A Cumulative Redeemable Perpetual Preferred Stock Offering
-
MTBC Announces Pricing of Series A Cumulative Redeemable Perpetual Preferred Stock Offering
-
CEVA (CEVA) PT Bumped to $27 at Chardan Capital Markets
-
Genius Brands International Announces $4.3 Million Private Placement
-
Integrated Device Technology (IDTI) PT Raised to $34 at Chardan Capital Markets
-
Vascular Biogenics (VBLT) PT Raised to $27.50 at Chardan Capital Markets
-
WaferGen Bio-systems Announces Successful Completion of $17.25 Million Public Offering
-
Chardan Capital Markets Starts Regenxbio Inc. (RGNX) at Buy
-
Blue Earth (BBLU) Enters $4M Registered Direct Offering of Common Stock, Warrants
-
Blue Earth Announces $4 Million Registered Direct Offering
-
WaferGen Bio-Systems (WGBS) Prices $15M Offering of Common Stock and Warrants
-
WaferGen Bio-systems Announces Pricing of $15 Million Underwritten Offering
-
ORBCOMM (ORBC) Second Batch of OG2 Closer to Launch, Chardan Capital Markets Says
-
Immune Pharmaceuticals (IMNP) PT Raised to $6.50 at Chardan Capital Markets
-
Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
-
Pre-Open Stock Movers 10/08: (JMG) (BMR) (EMC) Higher; (CSII) (ORIG) (SHAK) Lower (more...)
-
After-Hours Stock Movers 10/07: (NVLS) (LL) (LBIO) Higher; (CSII) (DB) (EXFO) Lower (more...)
-
Lion Biotechnologies (LBIO) PT Lifted 33% at Chardan Capital Markets to $20
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)
-
Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
-
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
-
Chardan Capital Markets Upgrades Amicus Therapeutics (FOLD) to Buy
-
Notable Analyst Rating Changes 9/30: (RF) (CP) (ESPR) Upgraded; (GPS) (GPC) (ITC) Downgraded
-
Pre-Open Stock Movers 09/30: (EZCH) (RENT) (WDC) Higher; (CUDA) (PLNT) (VRNT) Lower (more...)
-
UPDATE: Chardan Upgrades Esperion (ESPR) to Neutral But Maintains Negative Bias
-
Chardan Capital Cuts PT on Esperion Therapeutics (ESPR) to $29; EOP2 Minutes Worse than Expected
-
Chardan Capital Affirms VBL Therapeutics (VBLT) at 'Buy' Following Strong VB-111 Combo Phase 2 Data
-
Chardan Capital Assumes Vuzix Corp. (VUZI) at Buy
-
Axovant Sciences (AXON) Defended at RBC Capital

